Review





Similar Products

sars cov 2 delta variant  (R&D Systems)
94
R&D Systems sars cov 2 delta variant
Analysis <t>of</t> <t>the</t> <t>SARS-CoV-2</t> growth in hiPSC-derived lung organoids treated with tobramycin or sisomicin. ( a ) A schematic representation of the protocol for infection assay using hiPSC-derived lung organoids infected with SARS-CoV-2 B.1.617.2 (Delta) or BA.1 (Omicron) variants. ( b ) Cell viability in non-infected hiPSC-derived lung organoids treated without (Mock) or with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) was assessed using the WST-8 assay. Data are presented as mean ± SEM and are representative of three independent experiments. ( c, d ) The viral copy number in the culture supernatant of hiPSC-derived lung organoids treated with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) in combination with infection by the SARS-CoV-2 Delta ( c ) or Omicron ( d ) variants were measured by RT-qPCR. “Mock” indicates uninfected and untreated control samples. Data are presented as mean ± SEM and are representative of three independent experiments. p = 0.053, p = 0.088, and *** p < 0.001 indicates significant differences compared to the Water-treated infected group, as determined by one-way ANOVA followed by Dunnett’s post hoc test. Results were reproducible through these experiments.
Sars Cov 2 Delta Variant, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/b+1+617+2+variant/Recombinant+SARS-CoV-2+B%2E1%2E617%2E2+S+GCN4-IZ+Avi+Protein%2C+CF/pmc13096270-53-8-16
Average 94 stars, based on 1 article reviews
sars cov 2 delta variant - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
inhibited variant b 1 617 2  (Pfizer Inc)
86
Pfizer Inc inhibited variant b 1 617 2
Analysis <t>of</t> <t>the</t> <t>SARS-CoV-2</t> growth in hiPSC-derived lung organoids treated with tobramycin or sisomicin. ( a ) A schematic representation of the protocol for infection assay using hiPSC-derived lung organoids infected with SARS-CoV-2 B.1.617.2 (Delta) or BA.1 (Omicron) variants. ( b ) Cell viability in non-infected hiPSC-derived lung organoids treated without (Mock) or with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) was assessed using the WST-8 assay. Data are presented as mean ± SEM and are representative of three independent experiments. ( c, d ) The viral copy number in the culture supernatant of hiPSC-derived lung organoids treated with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) in combination with infection by the SARS-CoV-2 Delta ( c ) or Omicron ( d ) variants were measured by RT-qPCR. “Mock” indicates uninfected and untreated control samples. Data are presented as mean ± SEM and are representative of three independent experiments. p = 0.053, p = 0.088, and *** p < 0.001 indicates significant differences compared to the Water-treated infected group, as determined by one-way ANOVA followed by Dunnett’s post hoc test. Results were reproducible through these experiments.
Inhibited Variant B 1 617 2, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/b+1+617+2+variant/1+2+617+b+inhibited+variant/us12516107-354-14-9
Average 86 stars, based on 1 article reviews
inhibited variant b 1 617 2 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
delta full length trimer spike variant  (Sino Biological)
94
Sino Biological delta full length trimer spike variant
Analysis <t>of</t> <t>the</t> <t>SARS-CoV-2</t> growth in hiPSC-derived lung organoids treated with tobramycin or sisomicin. ( a ) A schematic representation of the protocol for infection assay using hiPSC-derived lung organoids infected with SARS-CoV-2 B.1.617.2 (Delta) or BA.1 (Omicron) variants. ( b ) Cell viability in non-infected hiPSC-derived lung organoids treated without (Mock) or with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) was assessed using the WST-8 assay. Data are presented as mean ± SEM and are representative of three independent experiments. ( c, d ) The viral copy number in the culture supernatant of hiPSC-derived lung organoids treated with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) in combination with infection by the SARS-CoV-2 Delta ( c ) or Omicron ( d ) variants were measured by RT-qPCR. “Mock” indicates uninfected and untreated control samples. Data are presented as mean ± SEM and are representative of three independent experiments. p = 0.053, p = 0.088, and *** p < 0.001 indicates significant differences compared to the Water-treated infected group, as determined by one-way ANOVA followed by Dunnett’s post hoc test. Results were reproducible through these experiments.
Delta Full Length Trimer Spike Variant, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/b+1+617+2+variant/SARS-CoV-2+B%2E1%2E617%2E2+Spike+S1%2BS2+trimer+Protein/pm40069439-72-25-31
Average 94 stars, based on 1 article reviews
delta full length trimer spike variant - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
b 1 617 2 delta variants  (ATCC)
94
ATCC b 1 617 2 delta variants
Analysis <t>of</t> <t>the</t> <t>SARS-CoV-2</t> growth in hiPSC-derived lung organoids treated with tobramycin or sisomicin. ( a ) A schematic representation of the protocol for infection assay using hiPSC-derived lung organoids infected with SARS-CoV-2 B.1.617.2 (Delta) or BA.1 (Omicron) variants. ( b ) Cell viability in non-infected hiPSC-derived lung organoids treated without (Mock) or with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) was assessed using the WST-8 assay. Data are presented as mean ± SEM and are representative of three independent experiments. ( c, d ) The viral copy number in the culture supernatant of hiPSC-derived lung organoids treated with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) in combination with infection by the SARS-CoV-2 Delta ( c ) or Omicron ( d ) variants were measured by RT-qPCR. “Mock” indicates uninfected and untreated control samples. Data are presented as mean ± SEM and are representative of three independent experiments. p = 0.053, p = 0.088, and *** p < 0.001 indicates significant differences compared to the Water-treated infected group, as determined by one-way ANOVA followed by Dunnett’s post hoc test. Results were reproducible through these experiments.
B 1 617 2 Delta Variants, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/b+1+617+2+variant/Cladosporium+echinulatum+(Berkeley)+de+Vries%2C+anamorph/pm39928060-33-35-49
Average 94 stars, based on 1 article reviews
b 1 617 2 delta variants - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
k18 hace2 mice sars cov 2 delta variant b 1 617 2  (ATCC)
93
ATCC k18 hace2 mice sars cov 2 delta variant b 1 617 2
Analysis <t>of</t> <t>the</t> <t>SARS-CoV-2</t> growth in hiPSC-derived lung organoids treated with tobramycin or sisomicin. ( a ) A schematic representation of the protocol for infection assay using hiPSC-derived lung organoids infected with SARS-CoV-2 B.1.617.2 (Delta) or BA.1 (Omicron) variants. ( b ) Cell viability in non-infected hiPSC-derived lung organoids treated without (Mock) or with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) was assessed using the WST-8 assay. Data are presented as mean ± SEM and are representative of three independent experiments. ( c, d ) The viral copy number in the culture supernatant of hiPSC-derived lung organoids treated with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) in combination with infection by the SARS-CoV-2 Delta ( c ) or Omicron ( d ) variants were measured by RT-qPCR. “Mock” indicates uninfected and untreated control samples. Data are presented as mean ± SEM and are representative of three independent experiments. p = 0.053, p = 0.088, and *** p < 0.001 indicates significant differences compared to the Water-treated infected group, as determined by one-way ANOVA followed by Dunnett’s post hoc test. Results were reproducible through these experiments.
K18 Hace2 Mice Sars Cov 2 Delta Variant B 1 617 2, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/b+1+617+2+variant/Pseudomonas+putida+(Trevisan)+Migula/pm39221180-244-4-36
Average 93 stars, based on 1 article reviews
k18 hace2 mice sars cov 2 delta variant b 1 617 2 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
b 1 617 2 variant catalog number 40592 v08h90  (Sino Biological)
93
Sino Biological b 1 617 2 variant catalog number 40592 v08h90
Analysis <t>of</t> <t>the</t> <t>SARS-CoV-2</t> growth in hiPSC-derived lung organoids treated with tobramycin or sisomicin. ( a ) A schematic representation of the protocol for infection assay using hiPSC-derived lung organoids infected with SARS-CoV-2 B.1.617.2 (Delta) or BA.1 (Omicron) variants. ( b ) Cell viability in non-infected hiPSC-derived lung organoids treated without (Mock) or with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) was assessed using the WST-8 assay. Data are presented as mean ± SEM and are representative of three independent experiments. ( c, d ) The viral copy number in the culture supernatant of hiPSC-derived lung organoids treated with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) in combination with infection by the SARS-CoV-2 Delta ( c ) or Omicron ( d ) variants were measured by RT-qPCR. “Mock” indicates uninfected and untreated control samples. Data are presented as mean ± SEM and are representative of three independent experiments. p = 0.053, p = 0.088, and *** p < 0.001 indicates significant differences compared to the Water-treated infected group, as determined by one-way ANOVA followed by Dunnett’s post hoc test. Results were reproducible through these experiments.
B 1 617 2 Variant Catalog Number 40592 V08h90, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/b+1+617+2+variant/SARS-CoV-2+Spike+RBD+(L452R%2CT478K)+Protein/pm39192804-53-56-89
Average 93 stars, based on 1 article reviews
b 1 617 2 variant catalog number 40592 v08h90 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
s1 b 1 617 2 variant catalog number 40591 v49h2 b  (Sino Biological)
92
Sino Biological s1 b 1 617 2 variant catalog number 40591 v49h2 b
Analysis <t>of</t> <t>the</t> <t>SARS-CoV-2</t> growth in hiPSC-derived lung organoids treated with tobramycin or sisomicin. ( a ) A schematic representation of the protocol for infection assay using hiPSC-derived lung organoids infected with SARS-CoV-2 B.1.617.2 (Delta) or BA.1 (Omicron) variants. ( b ) Cell viability in non-infected hiPSC-derived lung organoids treated without (Mock) or with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) was assessed using the WST-8 assay. Data are presented as mean ± SEM and are representative of three independent experiments. ( c, d ) The viral copy number in the culture supernatant of hiPSC-derived lung organoids treated with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) in combination with infection by the SARS-CoV-2 Delta ( c ) or Omicron ( d ) variants were measured by RT-qPCR. “Mock” indicates uninfected and untreated control samples. Data are presented as mean ± SEM and are representative of three independent experiments. p = 0.053, p = 0.088, and *** p < 0.001 indicates significant differences compared to the Water-treated infected group, as determined by one-way ANOVA followed by Dunnett’s post hoc test. Results were reproducible through these experiments.
S1 B 1 617 2 Variant Catalog Number 40591 V49h2 B, supplied by Sino Biological, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/b+1+617+2+variant/SARS-CoV-2+Spike+S1+((157-158)+deletion%2C+T19R%2C+G142D%2C+E156G%2C+L452R%2C+T478K%2C+D614G%2C+P681R)+Protein+(His+%26+AVI+Tag)%2C+Biotinylated/pm39192804-53-49-89
Average 92 stars, based on 1 article reviews
s1 b 1 617 2 variant catalog number 40591 v49h2 b - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
sars cov 2 delta variant b 1 617 2  (ATCC)
93
ATCC sars cov 2 delta variant b 1 617 2
Analysis <t>of</t> <t>the</t> <t>SARS-CoV-2</t> growth in hiPSC-derived lung organoids treated with tobramycin or sisomicin. ( a ) A schematic representation of the protocol for infection assay using hiPSC-derived lung organoids infected with SARS-CoV-2 B.1.617.2 (Delta) or BA.1 (Omicron) variants. ( b ) Cell viability in non-infected hiPSC-derived lung organoids treated without (Mock) or with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) was assessed using the WST-8 assay. Data are presented as mean ± SEM and are representative of three independent experiments. ( c, d ) The viral copy number in the culture supernatant of hiPSC-derived lung organoids treated with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) in combination with infection by the SARS-CoV-2 Delta ( c ) or Omicron ( d ) variants were measured by RT-qPCR. “Mock” indicates uninfected and untreated control samples. Data are presented as mean ± SEM and are representative of three independent experiments. p = 0.053, p = 0.088, and *** p < 0.001 indicates significant differences compared to the Water-treated infected group, as determined by one-way ANOVA followed by Dunnett’s post hoc test. Results were reproducible through these experiments.
Sars Cov 2 Delta Variant B 1 617 2, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/b+1+617+2+variant/Pseudomonas+putida+(Trevisan)+Migula/pmc11364132-250-0-30
Average 93 stars, based on 1 article reviews
sars cov 2 delta variant b 1 617 2 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

Image Search Results


Analysis of the SARS-CoV-2 growth in hiPSC-derived lung organoids treated with tobramycin or sisomicin. ( a ) A schematic representation of the protocol for infection assay using hiPSC-derived lung organoids infected with SARS-CoV-2 B.1.617.2 (Delta) or BA.1 (Omicron) variants. ( b ) Cell viability in non-infected hiPSC-derived lung organoids treated without (Mock) or with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) was assessed using the WST-8 assay. Data are presented as mean ± SEM and are representative of three independent experiments. ( c, d ) The viral copy number in the culture supernatant of hiPSC-derived lung organoids treated with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) in combination with infection by the SARS-CoV-2 Delta ( c ) or Omicron ( d ) variants were measured by RT-qPCR. “Mock” indicates uninfected and untreated control samples. Data are presented as mean ± SEM and are representative of three independent experiments. p = 0.053, p = 0.088, and *** p < 0.001 indicates significant differences compared to the Water-treated infected group, as determined by one-way ANOVA followed by Dunnett’s post hoc test. Results were reproducible through these experiments.

Journal: Scientific Reports

Article Title: Glycan-binding properties of SARS-CoV-2 spike proteins: interactions with aminoglycoside antibiotics

doi: 10.1038/s41598-026-42404-3

Figure Lengend Snippet: Analysis of the SARS-CoV-2 growth in hiPSC-derived lung organoids treated with tobramycin or sisomicin. ( a ) A schematic representation of the protocol for infection assay using hiPSC-derived lung organoids infected with SARS-CoV-2 B.1.617.2 (Delta) or BA.1 (Omicron) variants. ( b ) Cell viability in non-infected hiPSC-derived lung organoids treated without (Mock) or with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) was assessed using the WST-8 assay. Data are presented as mean ± SEM and are representative of three independent experiments. ( c, d ) The viral copy number in the culture supernatant of hiPSC-derived lung organoids treated with Water (0.5%), remdesivir (10 µM), tobramycin (500 µM), or sisomicin (500 µM) ( n = 3 each) in combination with infection by the SARS-CoV-2 Delta ( c ) or Omicron ( d ) variants were measured by RT-qPCR. “Mock” indicates uninfected and untreated control samples. Data are presented as mean ± SEM and are representative of three independent experiments. p = 0.053, p = 0.088, and *** p < 0.001 indicates significant differences compared to the Water-treated infected group, as determined by one-way ANOVA followed by Dunnett’s post hoc test. Results were reproducible through these experiments.

Article Snippet: The commercially available biotinylated recombinant S-protein of the SARS-CoV-2 Delta variant (B.1.617.2; catalog No.: AVI10878 , R&D Systems) and Omicron variant (B.1.1.529; catalog No.: AVI11061 , R&D Systems) were dissolved in DDW to prepare a stock of 500 μg/mL.

Techniques: Derivative Assay, Infection, Quantitative RT-PCR, Control